Real-life persistence of golimumab in patients with chronic inflammatory rheumatic diseases: results of the 2-year observational GO-PRACTICE study - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Clinical and experimental rheumatology Année : 2020

Real-life persistence of golimumab in patients with chronic inflammatory rheumatic diseases: results of the 2-year observational GO-PRACTICE study

René-Marc Flipo
  • Fonction : Auteur
Florence Tubach
Philippe Goupille
  • Fonction : Auteur
Naoual Harid
  • Fonction : Auteur
  • PersonId : 1100160
Saannya Sequeira
  • Fonction : Auteur
Philippe Bertin
Bruno Fautrel

Résumé

Objective GO-PRACTICE aimed to evaluate the persistence, clinical response and safety of golimumab in adult patients with chronic inflammatory rheumatic disease. Methods Prospective observational study with 24 months of follow-up, involving 134 rheumatologists from public or private health establishments in France. The primary outcome was the persistence of golimumab 24 months after initial prescription. Cumulative persistence probabilities were determined from Kaplan-Meier estimates. Secondary outcomes included an evaluation of disease activity and golimumab safety profile.
Fichier principal
Vignette du fichier
Flipo et al. - 2020 - Real-life persistence of golimumab in patients wit.pdf (796.49 Ko) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-03240853 , version 1 (28-05-2021)

Identifiants

  • HAL Id : hal-03240853 , version 1

Citer

René-Marc Flipo, Florence Tubach, Philippe Goupille, Eric Lespessailles, Naoual Harid, et al.. Real-life persistence of golimumab in patients with chronic inflammatory rheumatic diseases: results of the 2-year observational GO-PRACTICE study. Clinical and experimental rheumatology, 2020. ⟨hal-03240853⟩
41 Consultations
144 Téléchargements

Partager

Gmail Facebook X LinkedIn More